Mushroom poisoning (mushroom toxicity) occurs after the ingestion of mushrooms that contain toxins, often in the context of foraging for nontoxic, similarly appearing mushrooms. Mushrooms are the fruiting bodies of a group of higher fungi that have evolved contemporaneously with plants for millions of years. They are widely distributed throughout the world. There are thousands of species of mushrooms, but only about 100 species of mushrooms cause symptoms when eaten by humans, and only 15-20 mushroom species are potentially lethal when ingested.
No simple rule exists for distinguishing edible mushrooms from poisonous mushrooms. In more than 95% of mushroom toxicity cases, poisoning occurs as a result of misidentification of the mushroom by an amateur mushroom hunter. In less than 5% of the cases, poisoning occurs after the mushroom is consumed for its mind-altering properties.
The severity of mushroom poisoning may vary, depending on the geographic location where the mushroom is grown, growth conditions, the amount of toxin delivered, and the genetic characteristics of the mushroom. Boiling, cooking, freezing, or processing may not alter the toxicity of some mushrooms.
Variations in clinical effects may depend on an individual’s susceptibility and on the presence of confounding factors such as contamination or co-ingestion. In general, children are often exposed to nontoxic mushrooms, while older persons are at greater risk for the development of serious complications with mushroom poisoning than are healthy young adults.
Mushroom exposure in children is an infrequent but perennial problem for parents and clinicians. Parental anxiety is generally high because of fears of unknown or untoward effects. The challenges for clinicians are to identify such poisonings, to discern whether poisoning has taken place, to order appropriate diagnostic studies, and to prescribe reasonable therapy. The varied nature of mushroom toxicities, their ubiquitous distribution, and the relative infrequency of the ingestions make these challenges difficult to meet.
Each poisonous mushroom species contains 1 or more toxins, which may be classified on the basis of the mushroom’s physiologic and clinical effects in humans, the target organ toxicity, and the time to symptom onset. The clinical spectrum and toxicity vary with the following factors:
Geographic location where the mushroom was grown
Individual response to the toxins
Diaz, in a review of mushroom poisoning cases reported in the literature over 50 years, classified mushroom poisoning into the following 3 major categories on the basis of the time from ingestion to the development of symptoms [1, 2] :
Early symptom category – Symptoms generally appear within the first 6 hours of mushroom ingestion and include gastrointestinal (GI), allergic, and neurologic syndromes
Late symptom category – Signs and symptoms begin to appear between 6 and 24 hours after ingestion and may include hepatotoxic, nephrotoxic, and erythromelalgic syndromes
Delayed symptom category – Symptoms appear more than 24 hours after ingestion and include mostly nephrotoxic syndromes
Cyclopeptides – Amatoxin
Muscimol and ibotenic acid
GI poisons are the most frequently encountered mushroom toxins. Amatoxins, gyromitrins, and orellanine are the toxins most commonly implicated in fatal mushroom poisonings worldwide. The amatoxins, and to a lesser extent the gyromitrins, are hepatotoxic. Gyromitrins are also epileptogenic. Orellanine and norleucine are nephrotoxic. Muscarine, psilocybin, muscimol, and ibotenic acid are CNS poisons. Coprine causes a disulfiramlike reaction when combined with alcohol.
Cyclopeptides include amatoxins (high toxicity), phallotoxins (medium toxicity), and virotoxins (no toxicity).
Amatoxins, which are responsible for more than 95% of mushroom-related fatalities in the United States, are cyclic octapeptides that are synthesized by some Amanita, Galerina, and Lepiota species (see the list below).
At least 5 subtypes of amatoxins are known, the only significant human toxin being alpha-amatoxin, which inhibits RNA polymerase II and protein synthesis. Alpha-amatoxin is rapidly absorbed by the GI tract, has limited protein binding, and may undergo enterohepatic recirculation. It is excreted in the urine and may be detected in the vomitus and feces. Hepatocellular damage is presumably caused by the formation of free radical intermediates.
Amanita phalloides (death cap), Amanita virosa (destroying angel), Amanita verna (fool’s mushroom), Amanita bisporigera, Galerina autumnalis (autumn skullcap), and Galerina sulcipes are the most common mushrooms implicated in liver injury and death amongst the amatoxin-containing mushrooms.
The other associated toxin in Amanita ingestions are the phallotoxins, specifically phalloidin, which produce a choleralike syndrome with vomiting and watery diarrhea, usually starting 6 hours after ingestion, although cases with both earlier and later onset have occurred. Many Lepiota species lack phallotoxins, so ingestion of these may not present with the onset of vomiting and diarrhea until after 12 hours post ingestion, or they may occasionally present only with symptoms of liver failure at 24 hours post ingestion.
Amanitin-containing mushroom species 
Amanita group, as follows:
Amanita phalloides (see the image below) 
Lepiota group, as follows:
Galerina group, as follows:
Gyromitrin is a volatile hydrazine derivative synthesized by certain species of false morel (Gyromitra esculenta) and is easily confused with the early false morel (Verpa bohemica). Gyromitrin poisoning typically occurs after ingestion of the toxin-containing mushrooms but may also result from inhalation of the cooking vapors during their preparation.
In the stomach, gyromitrin is rapidly hydrolyzed into acetaldehyde and N -methyl-N -formyl hydrazine (MFH), which is then slowly converted to N -methylhydrazine (MH). Both MFH and MH are toxic to humans. MFH inhibits a number of hepatic systems, including cytochrome P-450 and glutathione, and causes hepatic necrosis. Hepatocellular damage is presumably caused by the formation of free radical intermediates.
MH inhibits pyridoxine kinase and interferes with all the pyridoxine-requiring enzymes in the body, including those involved in the synthesis of gamma-aminobutyric acid (GABA). The reduction of GABA concentrations in the brain leads to CNS hyperexcitability and convulsions. Gyromitrin ingestion may also rarely result in methemoglobinemia, hemolysis, and renal failure.
Orellanine is a nephrotoxic compound that is synthesized by several species of Cortinarius mushrooms. Orellanine-containing species include Cortinarius orellanus and Cortinarius speciosissimus, both of which are commonly found in Europe and Japan but not in North America. Cortinarius species that may contain small amounts of orellanine include Cortinarius gentilis, Cortinarius rainierensis, and Cortinarius splendens henrici; however, there are very few confirmed cases of Cortinarius-induced renal failure in North America. [7, 8, 9]
Orellanine is colorless and crystalline in nature and may be converted into orelline, which itself may be toxic. Its main effects are on the renal tubular system, where it causes necrosis with relative sparing of the glomerular apparatus. Fatty degeneration of the liver and severe inflammatory changes in the intestine may accompany the renal damage. Cortinarius mushrooms also may elaborate other compounds, such as cortinarin A, B, and C, which exhibit a nephrotoxic potential in laboratory animals.
Other nephrotoxic mushrooms, such as Amanita smithiana and Amanita proxima, have also been associated with an acute oliguric renal failure. Amanita smithiana may be mistaken for the matsutake mushroom (Tricholoma magnivelare) by foragers. These mushrooms cause vomiting and diarrhea 1-12 hours after ingestion, followed by a transient elevation of transaminases, then oliguric renal failure in 3-6 days. It is important to note that renal failure occurs within days of ingestion, as opposed to orellanine-induced renal failure that has an onset over 1-2 weeks. Exposure to norleucine-containing mushrooms may require temporary hemodialysis.
Psilocybin and psilocin are elaborated by a number of mushroom genera, including Psilocybe cubensis, Psilocybe semilanceata (Liberty cap) , Panaeolus cyanescens (previously referred to as Copelandia species), Gymnopilus spectabili (Big Laughing Jim), Conocybe cyanopus, Psathyrella foenisecii, and several species of Pluteus. Psilocybin and psilocin are serotonin (5-HT2) agonists and, when ingested, cause psychedelic effects similar to those of lysergic acid diethylamide (LSD).
Amanita muscaria (fly agaric) and Amanita pantherina (panthercap) mushrooms synthesize ibotenic acid and muscimol, both of which are excitatory neurotoxins and may be mildly hallucinogenic.
Ibotenic acid is structurally similar to glutamic acid and acts as an agonist at the glutamic acid receptors (NMDA receptors) in the CNS. Ibotenic acid is decarboxylated in vivo to muscimol. Muscimol is structurally similar to GABA and acts as a GABA-receptor agonist. Amanita muscaria (fly agaric) and Amanita pantherina also may contain some anticholinergic substances and small amounts of muscarine, a cholinergic agent.
Muscarine stimulates M1 and M2 types of postganglionic cholinergic receptors (muscarinic receptors) in the autonomic nervous system. This action results in parasympathetic stimulation similar to that caused by the release of endogenous acetylcholine at postganglionic receptors of smooth muscle and exocrine glands. The action on muscarinic receptors produces a cholinergic syndrome that is characterized by sweating, bronchorrhea with shortness of breath, salivation, lacrimation, diarrhea, miosis, abdominal cramps, and rarely bradycardia.
There is negligible activity on nicotinic receptors; hence, muscle weakness, fasciculations, and paralysis are not present. Because muscarine is a quaternary amine, it does not readily cross the blood-brain barrier and does not directly cause CNS effects. Muscarine is not metabolized by cholinesterase and has a longer biologic half-life than acetylcholine does.
Mushrooms that contain muscarine are commonly found in yards, parks, and wooded areas throughout the United States, Europe, and Asia. Species from the genera Clitocybe and Inocybe (see the images below) are most commonly responsible for muscarinic mushroom poisoning in the United States.
Clitocybe dealbata (the sweating mushroom) may be confused with the edible fairy ring champignon (Marasmius oreadus) or sweetbread mushroom (Clitopilus prunulus). Omphalotus olearius (the Jack O’ Lantern mushroom; see the image below) may be confused with the edible chanterelle (Cantharellus cibarius). Other muscarine-containing mushrooms include species from the genera Boletus, Mycena, and Omphalotus. Although Amanita muscaria derives its name from the trace amounts of muscarine it contains, it does not cause clinical cholinergic toxicity.
Muscarine-containing mushrooms typically produce cholinergic symptoms such as sweating, facial flushing, salivation, lacrimation, vomiting, abdominal cramps, diarrhea, urination, and miosis; occasionally, bradycardia, hypotension, and dizziness develop. Symptoms typically occur within 1 hour of ingestion and last for 4-24 hours. In most cases, they resolve without drug therapy or with a dose of atropine. [10, 11]
A few species of mushrooms, including Coprinopsis atramentaria (formerly known as Coprinus atramentarius), commonly referred to as inky cap or tippler’s bane and mistaken for the edible Coprinus comatus (shaggy mane), produce coprine, an amino acid that is metabolized to 1-aminocyclopropanol in the human body. This metabolite blocks acetaldehyde dehydrogenase, and in the presence of alcohol, acetaldehyde builds up, resulting in a disulfiram reaction. The effects of 1-aminocyclopropanol may last as long as 72 hours after ingestion of the mushroom.
Ingestion of Paxillus involutus may result in the acute onset of abdominal pain, nausea, vomiting, and diarrhea within 30 minutes to 3 hours of ingestion, followed by an immune complex-mediated hemolytic anemia with hemoglobinuria, oliguria, anuria, and acute renal failure.
Hundreds of mushrooms contain toxins that can cause GI symptoms (eg, nausea, vomiting, diarrhea, and abdominal pain) similar to those observed with more dangerous mushrooms. They include Chlorophyllum molybdites (green gill), Boletus piperatus (pepper bolete), and Agaricus arvensis (horse mushroom), among many others.
An immune reaction is believed to be the cause of the bronchoalveolar allergic syndrome seen after inhalation of spores of some puffball (Lycoperdon) mushroom species.
Two species of mushrooms, Clitocybe acromelaga (in Japan) and Clitocybe amoenolens (in Europe), cause a painful burning sensation with reddening of the skin several days after eating them. In Europe, the Clitocybe amoenolens mushroom has been mistaken for the edible mushroom Lepista inversa. The suspected toxin is acromelic acid A.
The main causes of mushroom toxicity are as follows:
Incorrect identification of a mushroom (eg, by a novice mushroom harvester or by someone who mistakes a poisonous local variety for an edible variety that is native to where they learned to pick mushrooms); many species are similar enough in appearance to confuse an inexperienced or insufficiently informed mushroom hunter
Unintentional ingestion by a child who found mushrooms growing in yards or outdoor play areas
Intentional ingestion by a person with euphoric intent (substance abuse)
Rare causes are as follows:
Intentional ingestion by a suicidal person
Foul play in which an individual is poisoned by someone else
Inadvertent poisoning from dried mushrooms purchased on the Internet or from other sources for which the composition of the mushroom is unreliable or the mushroom might be contaminated with unknown toxic compounds
Accidental poisoning accounts for more than 95% of the cases of mushroom intoxications; most of the remaining cases are due to intentional ingestion of the mushrooms for their mind-altering properties.
Cyclopeptide (amatoxin) poisoning most commonly is due to the following:
Amanita species (ie, bisporigera, ocreata, phalloides, tenuifolia, virosa, verna)
Galerina species (ie, autumnalis, sulcipes, marginata)
Lepiota species (brunneoincartata, helveola, josserandii, subincarnata)
Gyromitrin (monomethylhydrazine) poisoning is commonly due to Gyromitra esculenta.
Orellanine poisoning is commonly due to Cortinarius orellanus and Cortinarius speciosissimus.
Norleucine nephrotoxicity is due to Amanita smithiana and Amanita proxima.
Psilocybin and psilocin poisoning are commonly due to various Psilocybe species (semilenciata, and cubensis, among others), but it also may be due to the ingestion of many Panaeolus species, Gymnopilusspectabilis, Psathyrella foenisecii, and Psathyrella sepulcharis.
Ibotenic acid and muscimol poisonings are commonly due to some Amanita species (gemmata, muscaria, pantherina, and cokeri).
Muscarine poisoning is commonly due to Clitocybe species (dealbata, dilatata, illudens, and nebulens) and Omphalotus olearius (Jack O’ Lantern mushroom). Most Inocybe species also contain muscarine and may result in muscarinelike symptoms. Additionally, some Amanita species (muscaria, gemmata, pantherina, and parcivolvata) and some Boletus species contain small amounts of muscarine, along with other toxins.
Coprine poisoning is commonly due to ingestion of Coprinus and related mushrooms, including Coprinus atramentaria. Clitocybe clavipes may also contain coprine. Coprine causes a disulfiramlike reaction if ingested with alcohol.
Immunoallergic reactions resulting in hemolysis, hemoglobinuria, and immune-complex–mediated renal failure have occurred after the ingestion of Paxillus involutus. In Europe, Paxillus involutus has been reported to cause severe illness and death due to a Paxillus syndrome, which is characterized by abdominal cramps, diaphoresis, ice-cold extremities, weakness, loss of consciousness, and circulatory collapse.
Bronchoalveolar allergic syndrome results from the inhalation of spores of many Lycoperdon (puffball) species.
Rhabdomyolysis with renal failure has been reported after the ingestion of Tricholomaflavovirens (also know as Tricholoma equestre) in France and with Russula subnigricans in Taiwan.
Clitocybe acromelaga (in Japan) and Clitocybe amoenolens (in Europe) cause erythromelalgia.
The mushrooms that cause GI symptoms when ingested by humans include many of the “little brown mushrooms.” Additionally, Chlorophyllum species (esculentum and molybdites), Clitocybe nebularis, and Laetarius species cause GI irritation only.
Accidental poisonings tend to occur most commonly in the spring and fall, when mushroom species are at the peak of their fruiting stage. In general, most ingestions result in minor GI illness, with only the most severe requiring medical attention. Because the number of unreported cases is unknown, accurate figures regarding the frequency of mushroom poisoning are difficult to obtain. Cases usually are sporadic, and a few outbreaks have been reported.
During the 10-year period from 2001 to 2011, 83,140 mushroom ingestions were reported to US Poison Control Centers; of these, 64,534 (77.6%) were pediatric ingestions and 48,437 (58.3%) occurred in children younger than 6 years. A total of 48,423 (58.2%) patients were male. The majority of ingestions, 65,255 (78.5%), were unintentional. Identification was made in only 4,232 (5.1%) exposures and included 185 distinct species. The 5 most common species (number of identifications) were (1) Morchella angusticeps (507), (2) Chlorophyllum molybdites (374), (3) Amanita muscaria (319), (4) Lycoperdon candidum (228), and (5) Calvatia lepidophora (175). The toxin group was identified in 12,147 (14.6%) of ingestions.
The toxin groups and number of cases with identification were as follows:
Muscimol (ibotenic acid) (480)
Monomethylhydrazine (MMH) (448)
Hallucinogenics (psilocybin and psilocin) (8375)
GI irritants (1866)
Orellanine (41) (none confirmed)
Of the symptomatic cases, effects were minor in 10,953 (56.5%), moderate in 7,804 (40.3%), major in 568 (2.9%), and fatal in 45 (0.2%). Of the 614 cases of major effect or death, a species was identified in 64 (10.4%).
The 5 most common species (number of cases) identified as responsible for major effects or death were Amanita phalloides (27) [6, 12] , Amanita muscaria (22), Amanita pantherina (9), Amanita smithiana/proxima/pseudoporphyria (5), and Amanita bisporigera (3). Of the 97 cases in which Amanita phalloides was identified, 23 (23.7%) resulted in major effects and 4 (4.1%) in death. 
Mushroom foraging is common in Russia, Asia, and Europe; however, accurate figures regarding the incidence of mushroom toxicity (mushroom poisoning) are difficult to obtain. Outbreaks of severe mushroom poisoning have occurred in Europe, Russia, the Middle East, and the Far East. In April 2008, an outbreak of mushroom poisonings in the Upper Assam part of India claimed more than 30 lives.
Adults are frequently involved as foragers for edible mushrooms. Because of errors in identification, they may ingest toxin-containing mushrooms that resemble nontoxic varieties. Adults and adolescents may also be inadvertently poisoned when they intentionally consume mushrooms, picked from the ground or purchased dried, to achieve intoxication. Young children may be poisoned by mushrooms when they unintentionally eat mushrooms found outside, typically in yards or outdoor play areas.
Children and elderly patients are at the greatest risk for toxicity. A report from the North American Mycological Association (NAMA) case registry suggests that mushroom toxins may also be transferred to nursing infants through mothers’ milk.  According to the 2014 annual report from the AAPCC National Poison Data System, 3562 of 6117 total single mushroom exposures were reported in those younger than 6 years; 528 exposures were reported in those aged 6-12 years, 421 in those aged 13 to 19, and 1402 were reported in those older than 19 years. 
To a great extent, morbidity and mortality depend on the patient’s age and general health. Children and elderly persons are at the greatest risk for toxicity. Rapid diagnosis and treatment can also alter mortality substantially.
With good supportive care, the mortality for amatoxin poisoning may be reduced from 50-60% to less than 5%.  In a retrospective analysis of amatoxin-poisoned patients, Giannini found that the evolution of hepatic transaminase levels and the prothrombin time over the initial 4 days were highly predictive of recovery or death. 
In a retrospective study of 144 amatoxin-poisoned patients seen between 1996 and 2009, Trabulus et al reported a mortality of 9.7% (14 patients).  Factors associated with a greater likelihood of death included the following:
Low mean arterial pressure
Low sodium values
High urea, hepatic transaminase, total bilirubin, lactate dehydrogenase (LDH), prothrombin time (PT), international normalized ratio (INR), and activated partial thromboplastin time (aPTT) values
Most patients recover from gyromitrin poisoning. In the United States, death from this event is rare, but in some areas of Europe, mushrooms containing gyromitrins account for the most mushroom fatalities.
Although orellanine poisoning is not found in the United States, mushrooms containing orellanine account for the most mushroom fatalities in some areas of Europe. A shorter time course between ingestion and toxicity portends a worse prognosis. Mild renal insufficiency may resolve a few months after the ingestion.
The prognosis for psilocybin poisoning is excellent; no fatalities were reported in the United States in 2008.
The prognosis for muscarine poisoning is excellent. Fatalities are very rare: from 1999 to 2009, 35 deaths due to mushrooms were reported to US poison control centers through the AAPCC, but none was attributed to muscarine mushroom poisoning. Many patients who ingest muscarine-containing mushrooms have minor or no symptoms; when symptoms do occur, they tend to be temporary and self-limited, lasting 6-24 hours. [10, 11] Most patients recover without drug therapy. However, a case report from Australia described a 53-year-old woman who ate 2 large muscarine-containing Rubinoboletus mushrooms and came to a hospital with a 2-hour history of headache, chest and abdominal pain, vomiting, and profuse sweating.  At 3 hours, she also developed diarrhea, and her condition deteriorated rapidly with hypotension, bradycardia, coma, and respiratory distress.
At 7 hours, the patient remained in shock and did not respond to resuscitative measures.  During the first hour of hemodialysis, she developed asystole. At 10 hours after ingestion, the patient died. Her partner had also eaten some of the mushrooms but promptly vomited and did not exhibit any toxic effects. Whether this mushroom grows in North America is unknown.
Education regarding the poisonous nature of wild mushrooms may act as a deterrent to mushroom foraging and ingestion. Patients ingesting coprine-containing mushrooms should be educated regarding the interaction with alcohol.
Diaz JH. Evolving global epidemiology, syndromic classification, general management, and prevention of unknown mushroom poisonings. Crit Care Med. 2005 Feb. 33(2):419-26. [Medline].
Diaz JH. Syndromic diagnosis and management of confirmed mushroom poisonings. Crit Care Med. 2005 Feb. 33(2):427-36. [Medline].
Berger KJ, Guss DA. Mycotoxins revisited: Part I. J Emerg Med. 2005 Jan. 28(1):53-62. [Medline].
Berger KJ, Guss DA. Mycotoxins revisited: Part II. J Emerg Med. 2005 Feb. 28(2):175-83. [Medline].
Goldfrank LR. Mushrooms. In: Nelson LS, Lewin NA, Howland MA, Hoffman RS, Goldfrank LR, Flomenbaum NE. Goldfrank’s Toxicologic Emergencies. 9th. New York: McGraw-Hill; 2011:1522-36.
Garcia J, Costa VM, Carvalho A, Baptista P, de Pinho PG, de Lourdes Bastos M, et al. Amanita phalloides poisoning: Mechanisms of toxicity and treatment. Food Chem Toxicol. 2015 Sep 12. 86:41-55. [Medline].
Judge BS, Ammirati JF, Lincoff GH, Trestrail JH 3rd, Matheny PB. Ingestion of a newly described North American mushroom species from Michigan resulting in chronic renal failure: Cortinarius orellanosus. Clin Toxicol (Phila). 2010 Jul. 48(6):545-9. [Medline].
Bouget J, Bousser J, Pats B, et al. Acute renal failure following collective intoxication by Cortinarius orellanus. Intensive Care Med. 1990. 16(8):506-10. [Medline].
Danel VC, Saviuc PF, Garon D. Main features of Cortinarius spp. poisoning: a literature review. Toxicon. 2001 Jul. 39(7):1053-60. [Medline].
Benjamin DR. Muscarine poisoning. In: Mushrooms: Poisons and Panaceas. New York, NY: WH Freeman; 1995:340-50.
Poisindex managements, mushrooms – muscarine / histamine. In: Poisindex System, internet database online [database online]. Greenwood Village (CO): Thomson Reuters (Healthcare); May 15, 2011.
Garcia J, Costa VM, Carvalho AT, Silvestre R, Duarte JA, Dourado DF, et al. A breakthrough on Amanita phalloides poisoning: an effective antidotal effect by polymyxin B. Arch Toxicol. 2015 Dec. 89 (12):2305-23. [Medline].
Hatten BW, McKeown NJ, Hendrickson RG, Horowitz BZ. The Epidemiology of Mushroom Ingestion Calls to US Poison Control Centers: 2001-2011 [abstract]. Clin Toxicol. 2012 Aug. 50(7):274-720.
Beug MW, Shaw M, Cochran KW. Summary of approximately 2000 reports in the NAMA registry. NAMA Case registry.
Mowry JB, Spyker DA, Brooks DE, McMillan N, Schauben JL. 2014 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 32nd Annual Report. Clin Toxicol (Phila). 2015 Dec. 53 (10):962-1147. [Medline].
Saviuc PF, Danel VC, Moreau PA, et al. Erythromelalgia and mushroom poisoning. J Toxicol Clin Toxicol. 2001. 39(4):403-7. [Medline].
Giannini L, Vannacci A, Missanelli A, Mastroianni R, Mannaioni PF, Moroni F, et al. Amatoxin poisoning: a 15-year retrospective analysis and follow-up evaluation of 105 patients. Clin Toxicol (Phila). 2007 Jun-Aug. 45(5):539-42. [Medline].
Trabulus S, Altiparmak MR. Clinical features and outcome of patients with amatoxin-containing mushroom poisoning. Clin Toxicol (Phila). 2011 Apr. 49(4):303-10. [Medline].
Pauli JL, Foot CL. Fatal muscarinic syndrome after eating wild mushrooms. Med J Aust. 2005 Mar 21. 182(6):294-5. [Medline].
Fischbein CB, Mueller GM, Leacock PR, Wahl MS, Aks SE. Digital imaging: a promising tool for mushroom identification. Acad Emerg Med. 2003 Jul. 10(7):808-11. [Medline].
West PL, Lindgren J, Horowitz BZ. Amanita smithiana mushroom ingestion: a case of delayed renal failure and literature review. J Med Toxicol. 2009 Mar. 5(1):32-8. [Medline].
Tomková J, Ondra P, Válka I. Simultaneous determination of mushroom toxins α-amanitin, β-amanitin and muscarine in human urine by solid-phase extraction and ultra-high-performance liquid chromatography coupled with ultra-high-resolution TOF mass spectrometry. Forensic Sci Int. 2015 Jun. 251:209-13. [Medline].
US Food and Drug Administration. FDA Drug Safety Communication: Serious CNS reactions possible when methylene blue is given to patients taking certain psychiatric medications. Available at http://www.fda.gov/Drugs/DrugSafety/ucm263190.htm. Accessed: July 27, 2011.
Tong TC, Hernandez M, Richardson WH 3rd, Betten DP, Favata M, Riffenburgh RH, et al. Comparative treatment of alpha-amanitin poisoning with N-acetylcysteine, benzylpenicillin, cimetidine, thioctic acid, and silybin in a murine model. Ann Emerg Med. 2007 Sep. 50(3):282-8. [Medline].
Enjalbert F, Rapior S, Nouguier-Soulé J, Guillon S, Amouroux N, Cabot C. Treatment of amatoxin poisoning: 20-year retrospective analysis. J Toxicol Clin Toxicol. 2002. 40(6):715-57. [Medline].
Wittebole X, Hantson P. Use of the molecular adsorbent recirculating system (MARS™) for the management of acute poisoning with or without liver failure. Clin Toxicol (Phila). 2011 Nov. 49(9):782-93. [Medline].
Bergis D, Friedrich-Rust M, Zeuzem S, Betz C, Sarrazin C, Bojunga J. Treatment of Amanita phalloides intoxication by fractionated plasma separation and adsorption (Prometheus®). J Gastrointestin Liver Dis. 2012 Jun. 21(2):171-6. [Medline].
Beuhler MC, Sasser HC, Watson WA. The outcome of North American pediatric unintentional mushroom ingestions with various decontamination treatments: an analysis of 14 years of TESS data. Toxicon. 2009;53:437-43.
[Guideline] Chyka PA, Seger D, Krenzelok EP, Vale JA. Position paper: Single-dose activated charcoal. Clin Toxicol (Phila). 2005. 43(2):61-87. [Medline].
Beug MW. 2013 NAMA Toxicology Committee Report North American Mushroom Poisonings. North American Mycological Association. Available at http://www.namyco.org/docs/2013_NAMA_Toxicology_Committee_Report.pdf. Accessed: December 29, 2015.
B Zane Horowitz, MD, FACMT Professor, Department of Emergency Medicine, Oregon Health and Sciences University School of Medicine; Medical Director, Oregon Poison Center; Medical Director, Alaska Poison Control System
B Zane Horowitz, MD, FACMT is a member of the following medical societies: American College of Medical Toxicology
Disclosure: Nothing to disclose.
Robert G Hendrickson, MD Associate Professor of Emergency Medicine, Oregon Health and Science University School of Medicine; Attending Physician, Medical Director, Emergency Management Program, Department of Emergency Medicine, Oregon Health and Science University Hospital and Health Systems; Associate Medical Director, Director, Fellowship in Medical Toxicology, Disaster Preparedness Coordinator, Oregon Poison Center; Clinical Toxicologist, Alaska Poison Center and Guam Poison Center
Robert G Hendrickson, MD is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Emergency Physicians, American College of Medical Toxicology, Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.
Asim Tarabar, MD Assistant Professor, Director, Medical Toxicology, Department of Emergency Medicine, Yale University School of Medicine; Consulting Staff, Department of Emergency Medicine, Yale-New Haven Hospital
Disclosure: Nothing to disclose.
William Banner Jr, MD, PhD Medical Director, Oklahoma Poison Control Center; Clinical Professor of Pharmacy, Oklahoma University College of Pharmacy-Tulsa; Adjunct Clinical Professor of Pediatrics, Oklahoma State University College of Osteopathic Medicine
William Banner Jr, MD, PhD, is a member of the following medical societies: American College of Medical Toxicology
Disclosure: Nothing to disclose
Peter A Chyka, PharmD, FAACT, DABAT Professor and Executive Associate Dean, College of Pharmacy, University of Tennessee Health Science Center
Peter A Chyka, PharmD, FAACT, DABAT is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Clinical Pharmacy, and American Society of Health-System Pharmacists
Disclosure: Nothing to disclose.
Timothy E Corden, MD Associate Professor of Pediatrics, Co-Director, Policy Core, Injury Research Center, Medical College of Wisconsin; Associate Director, PICU, Children’s Hospital of Wisconsin
Disclosure: Nothing to disclose.
Laurie Robin Grier, MD Medical Director of MICU, Professor of Medicine, Department of Emergency Medicine, Anesthesiology and OBGYN, Section of Pulmonary and Critical Care Medicine, Louisiana State University Health Science Center at Shreveport
Laurie Robin Grier, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Society for Parenteral and Enteral Nutrition, and Society of Critical Care Medicine
Disclosure: Nothing to disclose.
Rania Habal, MD Assistant Professor, Department of Emergency Medicine, New York Medical College
Disclosure: Nothing to disclose.
Jorge A Martinez, MD, JD Clinical Professor, Department of Internal Medicine, Louisiana State University School of Medicine in New Orleans; Clinical Instructor, Department of Surgery, Tulane School of Medicine
Jorge A Martinez, MD, JD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Cardiology, American College of Emergency Physicians, American College of Physicians, and Louisiana State Medical Society
Disclosure: Nothing to disclose.
Michael E Mullins, MD Assistant Professor, Department of Emergency Medicine, Washington University School of Medicine
Disclosure: Johnson & Johnson stock ownership None; Savient Pharmaceuticals stock ownership None
Daniel R Ouellette, MD, FCCP Associate Professor of Medicine, Wayne State University School of Medicine; Consulting Staff, Pulmonary Disease and Critical Care Medicine Service, Henry Ford Health System
Disclosure: Boehringer Ingleheim Honoraria Speaking and teaching; Pfizer Honoraria Speaking and teaching; Astra Zeneca Honoraria Speaking and teaching
Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Medscape Salary Employment
Jeffrey R Tucker, MD Assistant Professor, Department of Pediatrics, Division of Emergency Medicine, University of Connecticut and Connecticut Children’s Medical Center
Disclosure: Merck Salary Employment
Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Nothing to disclose.
Research & References of Mushroom Toxicity|A&C Accounting And Tax Services